Malaria deaths have been decreasing over the last 10-15 years, with global mortality rates having fallen by 47% since 2000. While the World Health Organization (WHO) recommends the use of artemisinin-based combination therapies (ACTs) to combat malaria, the emergence of artemisinin resistant strains underscores the need to develop new antimalarial drugs. Recent in vivo efficacy improvements of the historical antimalarial ICI 56,780 have been reported, however, with the poor solubility and rapid development of resistance, this compound requires further optimization. A series of piperazine-containing 4(1H)-quinolones with greatly enhanced solubility were developed utilizing structure-activity relationship (SAR) and structure-property relationship (SPR) studies. Furthermore, promising compounds were chosen for an in vivo scouting assay to narrow selection for testing in an in vivo Thompson test. Finally, two piperazine-containing 4(1H)-quinolones were curative in the conventional Thompson test and also displayed in vivo activity against the liver stages of the parasite.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610884PMC
http://dx.doi.org/10.1021/acs.jmedchem.7b00738DOI Listing

Publication Analysis

Top Keywords

structure-property relationship
8
piperazine-containing 41h-quinolones
8
thompson test
8
design synthesis
4
synthesis orally
4
orally bioavailable
4
bioavailable piperazine
4
piperazine substituted
4
substituted 41h-quinolones
4
41h-quinolones potent
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!